Zanubrutinib在B细胞淋巴瘤中的临床应用  

Clinical Application of Zanubrutinib in B-Cell Lymphoma——Review

作　　者：唐潇 邹文蓉[1] 彭鹏[1] 白洋禄 TANG Xiao;ZOU Wen-Rong;PENG Peng;BAI Yang-Lyu(Department of Hematology,Sichuan Mianyang 404 Hospital,Mianyang 621000,Sichuan Province,China)

机构地区：[1]四川绵阳四0四医院血液科,四川绵阳621000

出　　处：《中国实验血液学杂志》2022年第3期965-969,共5页Journal of Experimental Hematology

基　　金：四川省医学会科研基金(S17058)。

摘　　要：Zanubrutinib是我国自主研发的一种具有高选择性的二代布鲁顿酪氨酸激酶(BTK)抑制剂,也是首次获得美国食品及药物管理局(FDA)批准的新型抗肿瘤药物。近年来,随着分子靶向药物诞生,部分B细胞淋巴瘤的治疗逐渐进入了无化疗的靶向时代,免疫治疗也逐渐被应用于临床,特别是在一些复发难治的淋巴瘤中,都显示出了深度持久的缓解及良好的安全性,为精准治疗奠定了基础。本文主要是针对zanubrutinib在B细胞淋巴瘤中的临床应用及最新研究进展作一综述。Zanubrutinib is a highly selective second-generation BTK inhibitor developed in China and first approved by the U.S. Food and Drug Administration(FDA) as a novel antineoplastic drug. In recent years, with the birth of molecularly targeted drugs, the treatment of B-cell lymphoma have entered the era of targeted therapy, and immunotherapy has been widely accepted. Especially in some relapsed and refractory lymphomas, zanubrutinib has shown deep and sustained remissions and a favorable safety, which lays a foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.

关 键 词：布鲁顿酪氨酸激酶 zanubrutinib B细胞淋巴瘤 靶向治疗 

分 类 号：R733.3[医药卫生—肿瘤]